
    
      The primary hypothesis is that high dose vitamin D3 plus standard dose vitamin D3 prevents
      the worsening of musculoskeletal symptoms when compared to a standard dose vitamin D3
      treatment. This protocol will examine the relationship between vitamin D levels
      (25-hydroxyvitamin D) and various quality of life measures in women being treated with
      letrozole as standard care for early stage breast cancer. All subjects received letrozole and
      a standard dose of vitamin D3 (600 IU daily). Randomization was between high dose vitamin D3
      (30,000 IU once per week) vs. a blinded, matched placebo,
    
  